Bengaluru: Maiva Pharma, a global Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) specialising in sterile injectables, inaugurated its new manufacturing facility at Shoolagiri, Tamil Nadu, India.

The facility marks a significant milestone in Maiva’s growth journey, further strengthening its position as a trusted partner to global pharmaceutical and biotechnology companies for the development and manufacturing of generic and complex sterile injectable products.

Spread across a 22-acre site, the new facility has been designed to support current and future market requirements through advanced manufacturing technologies, flexible production capabilities, and world-class quality systems. Upon full development, the facility will house six manufacturing lines capable of producing a broad range of sterile injectable dosage forms, including vials, pre-filled syringes (PFS), cartridges, suspension products, and lyophilized formulations.

As part of the Phase 1 expansion, Maiva Pharma has commissioned three dedicated manufacturing lines comprising a high-speed vial filling line, a combined pre-filled syringe and cartridge line, and a lyophilization line. The facility is further supported by advanced Quality Control chemical laboratories and state-of-the-art Microbiology laboratories, enabling comprehensive analytical testing and quality assurance functions in-house.

A key highlight of the facility is its advanced isolator-based manufacturing lines for liquid vials, pre-filled syringes, cartridges, and lyophilized vials. The isolator technology enhances sterility assurance, operational efficiency, and manufacturing flexibility while supporting the production of a wide range of injectable products for regulated global markets.

Source: Medical Dialogues - June 16,2026